BackProMIS Neurosciences Overview

ProMIS Neurosciences Other Current Assets

Track ProMIS Neurosciences's other current assets ($3.2M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Other Current Assets
$3.23M
34.56% YoYΔ $-1.71M vs prior year quarter

Peer average / median

Loading

ProMIS Neurosciences Other Current Assets History

Loading

ProMIS Neurosciences vs. peers: Other Current Assets Comparison

Loading

ProMIS Neurosciences Other Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

ProMIS Neurosciences (PMN) FAQ

ProMIS Neurosciences's other current assets stands at $3.2M as of June 2026. That compares with $4.9M in the prior-year period — down 34.6% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

ProMIS Neurosciences reported $3.2M in other current assets versus $4.9M a year earlier — a 34.6% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $4.9M in the prior-year period — down 34.6% year over year. Sustained growth in other current assets can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how ProMIS Neurosciences's other current assets evolved across reporting periods, while the comparison chart places PMN next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, other current assets is commonly used to spot outliers. ProMIS Neurosciences's reading of $3.2M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.